Abstract

THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY/DRUG CONJUGATE

As treatment effective for HER2-expressing cancer having resistance or refractoriness to an existing anti-HER2 drug, there are provided a therapeutic agent and a treatment method using an antibody-drug conjugate in which a linker and a drug represented by the formula: -(Succinimid-3-yl-N)-$CH_2CH_2CH_2CH_2CH_2$-C(=O)-GGFG-NH-CH_2-O-CH_2-C(=O)-(NH-DX) are conjugated to an anti-HER2 antibody.

[FIG. 3]